Not yet recruiting
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
NCT07816978· Phase 4· Sahlgrenska University Hospital· Source
Recruiting
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
NCT05139849· Phase 3· Tiohundra AB· Source
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
NCT07843472· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Not yet recruiting
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00· Phase 2· Oslo Universitetssykehus HF· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Not yet recruiting
COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial
2026-526122-41-00· Phase 2· Uppsala University Hospital· Source
Not yet recruiting
Next generation StaR-TREC
2025-522955-25-00· Phase 4· Vaestra Goetalandsregionen· Source
Active, not recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· Phase 3· Neurocrine Biosciences· Source
Active, not recruiting
An open-label, non-randomised safety and tolerability Proof of Concept Trial to examine multiple dosing addition of glycocholate (GC) and butyrate (B) to increase Ca absorption in healthy female participants that have undergone Roux-en-Y gastric bypass (BAFA)
2024-511124-14-00· Phase 1/2· Vaestra Goetalandsregionen· Source
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793· Phase 2· AstraZeneca· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Recruiting
OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety
NCT05641623· Phase 2· University Of Gothenburg· Source
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Recruiting
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
NCT06401616· Phase 4· Odense University Hospital· Source
Recruiting
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
NCT04920149· Phase 2· Ann-Sofie Backman· Source
Recruiting
Treating Diabetic Foot Ulcers, Comparing Two Topical Antimicrobial Agents, Dakin´s and Prontosan
NCT05132179· Phase 3· Vastra Gotaland Region· Source
Active, not recruiting
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
NCT05214183· Phase 2· Nordic Lymphoma Group· Source
Recruiting
OSU6162 in Bipolar Depression (OBID)
NCT05296356· Phase 2· Göteborg University· Source
Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized placebo-controlled study with tadalafil
2023-504592-24-00· Phase 2· Karolinska Institutet· Source
Completed
Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis
NCT03831776· Phase 2· St. Olavs Hospital· Source
Active, not recruiting
ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma
2024-514275-18-00· Phase 2/3· Region Skane· Source
Active, not recruiting
Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
NCT02945566· Phase 2/3· University of Birmingham· Source
Active, not recruiting
Adjuvant Low Dose Aspirin in Colorectal Cancer
NCT02647099· Phase 3· Anna Martling· Source